South & Central America T Cell Therapy Market Forecast to 2030 - Regional Analysis - by Modality (Research and Commercialized), Therapy Type [CAR T-cell Therapy and T-cell Receptor (TCR)-based], and Indication (Hematologic Malignancies and Solid Tumors)
The South & Central America T cell therapy market was valued at US$ 84.11 million in 2022 and is expected to reach US$ 265.59 million by 2030; it is estimated to grow at a CAGR of 15.5% from 2022 to 2030.
Increasing Number of T-Cell Therapy Approvals Fuels the South & Central America T Cell Therapy Market
Targeted treatment, faster and more efficient recovery, and reduced side effects are among the advantages of t cell therapy. Globally, cell therapies are widely adopted owing to the availability of various approval:
• In 2023: Kite, a Gilead Company announced launching operations in Saudi Arabia, Singapore, and Brazil as part of its commercial expansion. Kite has filed regulatory applications for its CAR T-cell therapy products in each of the three nations.
• For instance, in June 2022, Bristol Myers Squibb received FDA approval for Breyanzi (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adult patients with large B-cell lymphoma (LBCL).
• In February 2022, the US Food and Drug Administration (FDA) approved Yescarta (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first line chemoimmunotherapy or that relapses within 12 months of first line chemoimmunotherapy. Yescarta is the first CAR T-cell therapy to receive a National Comprehensive Cancer Network (NCCN) Category 1 recommendation.
• In February 2022, the FDA approved ciltacabtagene autoleucel (brand name CARVYKTI) for treating adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
• In January 2022, the FDA approved Kimmtrak (tebentafusp-tebn) for treating unresectable or metastatic uveal melanoma patients who are HLA-A*02:01 positive.
• In March 2021, Abecma (idecabtagene vicleucel) was approved by the FDA for treating relapsed or refractory multiple myeloma. The treatment is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T-cell immunotherapy indicated for treating adult patients with refractory multiple myeloma.
Therefore, the increasing number of approvals for T-cell therapies is fueling the market growth.
South & Central America T Cell Therapy Market Overview
The South & Central America T-cell therapy market is limited to Brazil as the products are only approved and commercially available in the country. According to the Brazilian Journal of Cancerology, it is estimated that ~704,000 new cases of cancer are expected during 2023-2025. More than 12,000 non-Hodgkin lymphoma (NHL) cases in Brazil are estimated to be diagnosed yearly. The Brazilian Health Regulatory Agency (ANVISA) has approved two CAR T-cell therapies in Brazil: tisagenlecleucel (by Novartis) for pediatric patients and young adults with RR B-cell acute lymphoblastic leukemia (ALL) and adults with relapsed/refractory (RR) diffuse large B-cell lymphoma, and ciltacabtagene autoleucel (cilta-cel) for patients with relapsed/refractory multiple myeloma (RRMM). Moreover, in August 2022, Kite, a Gilead Company, expanded its business by launching operations in Brazil, Singapore, and Saudi Arabia. Kite has submitted regulatory applications for its CAR T-cell therapy products. The rising cases of cancer and lymphoma, and the increasing number of applications and clinical trials for T-cell therapies are expected to boost the demand in the coming years.
South & Central America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
South & Central America T Cell Therapy Market Segmentation
The South & Central America T cell therapy market is segmented into modality , therapy type, indication, and country.
Based on modality, the South & Central America T cell therapy market is bifurcated into research and commercialized. The commercialized segment held a larger market share in 2022.
Based on therapy type, the South & Central America T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held a larger market share in 2022.
Based on indication, the South & Central America T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held the largest market share in 2022.
Based on country, the South & Central America T cell therapy market is limited to Brazil. Brazil dominated the South & Central America T cell therapy market share in 2022.
Bristol-Myers Squibb Co, Gilead Sciences Inc, Janssen Global Services LLC, and Novartis AG are some of the leading companies operating in the South & Central America T cell therapy market.
Increasing Number of T-Cell Therapy Approvals Fuels the South & Central America T Cell Therapy Market
Targeted treatment, faster and more efficient recovery, and reduced side effects are among the advantages of t cell therapy. Globally, cell therapies are widely adopted owing to the availability of various approval:
• In 2023: Kite, a Gilead Company announced launching operations in Saudi Arabia, Singapore, and Brazil as part of its commercial expansion. Kite has filed regulatory applications for its CAR T-cell therapy products in each of the three nations.
• For instance, in June 2022, Bristol Myers Squibb received FDA approval for Breyanzi (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adult patients with large B-cell lymphoma (LBCL).
• In February 2022, the US Food and Drug Administration (FDA) approved Yescarta (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first line chemoimmunotherapy or that relapses within 12 months of first line chemoimmunotherapy. Yescarta is the first CAR T-cell therapy to receive a National Comprehensive Cancer Network (NCCN) Category 1 recommendation.
• In February 2022, the FDA approved ciltacabtagene autoleucel (brand name CARVYKTI) for treating adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
• In January 2022, the FDA approved Kimmtrak (tebentafusp-tebn) for treating unresectable or metastatic uveal melanoma patients who are HLA-A*02:01 positive.
• In March 2021, Abecma (idecabtagene vicleucel) was approved by the FDA for treating relapsed or refractory multiple myeloma. The treatment is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T-cell immunotherapy indicated for treating adult patients with refractory multiple myeloma.
Therefore, the increasing number of approvals for T-cell therapies is fueling the market growth.
South & Central America T Cell Therapy Market Overview
The South & Central America T-cell therapy market is limited to Brazil as the products are only approved and commercially available in the country. According to the Brazilian Journal of Cancerology, it is estimated that ~704,000 new cases of cancer are expected during 2023-2025. More than 12,000 non-Hodgkin lymphoma (NHL) cases in Brazil are estimated to be diagnosed yearly. The Brazilian Health Regulatory Agency (ANVISA) has approved two CAR T-cell therapies in Brazil: tisagenlecleucel (by Novartis) for pediatric patients and young adults with RR B-cell acute lymphoblastic leukemia (ALL) and adults with relapsed/refractory (RR) diffuse large B-cell lymphoma, and ciltacabtagene autoleucel (cilta-cel) for patients with relapsed/refractory multiple myeloma (RRMM). Moreover, in August 2022, Kite, a Gilead Company, expanded its business by launching operations in Brazil, Singapore, and Saudi Arabia. Kite has submitted regulatory applications for its CAR T-cell therapy products. The rising cases of cancer and lymphoma, and the increasing number of applications and clinical trials for T-cell therapies are expected to boost the demand in the coming years.
South & Central America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
South & Central America T Cell Therapy Market Segmentation
The South & Central America T cell therapy market is segmented into modality , therapy type, indication, and country.
Based on modality, the South & Central America T cell therapy market is bifurcated into research and commercialized. The commercialized segment held a larger market share in 2022.
Based on therapy type, the South & Central America T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held a larger market share in 2022.
Based on indication, the South & Central America T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held the largest market share in 2022.
Based on country, the South & Central America T cell therapy market is limited to Brazil. Brazil dominated the South & Central America T cell therapy market share in 2022.
Bristol-Myers Squibb Co, Gilead Sciences Inc, Janssen Global Services LLC, and Novartis AG are some of the leading companies operating in the South & Central America T cell therapy market.
1. INTRODUCTION
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 South & Central America T Cell Therapy Market, by Country (US$ Million)
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. SOUTH & CENTRAL AMERICA T CELL THERAPY MARKET - KEY INDUSTRY DYNAMICS
4.1 Market Drivers:
4.1.1 Growing Burden of Cancer Worldwide
4.1.2 Increasing Number of T-Cell Therapy Approvals
4.2 Market Restraints
4.2.1 Side-effects of CAR T-Cell Therapy
4.3 Market Opportunities
4.3.1 Growing Investment in T-Cell Therapy
4.4 Future Trends
4.4.1 Rising Number of CAR T-Cell Therapies in Clinical Trials
4.5 Impact Analysis:
5. T CELL THERAPY MARKET - SOUTH & CENTRAL AMERICA MARKET ANALYSIS
5.1 South & Central America T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030
6. SOUTH & CENTRAL AMERICA T CELL THERAPY MARKET - REVENUE AND FORECAST TO 2030 - BY MODALITY.
6.1 Overview
6.2 South & Central America T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
6.3 Research
6.3.1 Overview
6.3.2 Research: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Commercialized
6.4.1 Overview
6.4.2 Commercialized: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7. SOUTH & CENTRAL AMERICA T CELL THERAPY MARKET - REVENUE AND FORECAST TO 2030 - BY THERAPY TYPE
7.1 Overview
7.2 South & Central America T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
7.3 CAR T-cell Therapy
7.3.1 Overview
7.3.2 CAR T-cell Therapy: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 T-cell Receptor (TCR)-based.
7.4.1 Overview
7.4.2 T-cell Receptor (TCR)-based: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8. SOUTH & CENTRAL AMERICA T CELL THERAPY MARKET - REVENUE AND FORECAST TO 2030 - BY INDICATION
8.1 Overview
8.2 South & Central America T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
8.3 Hematologic Malignancies
8.3.1 Overview
8.3.2 Hematologic Malignancies: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.3.3 South & Central America T Cell Therapy Market , by Haematological Malignancies, 2020-2030 (US$ Million)
8.4 Solid Tumor
8.4.1 Overview
8.4.2 Solid Tumor: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
9. SOUTH & CENTRAL AMERICA T CELL THERAPY MARKET - COUNTRY ANALYSIS
9.1 Overview
9.1.1 South & Central America T Cell Therapy Market by Country
9.1.1.1 Brazil
9.1.1.1.1 Brazil: South & Central America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.1.2 Brazil: South & Central America T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
9.1.1.1.3 Brazil: South & Central America T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.1.4 Brazil: South & Central America T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.1.4.1 Brazil: South & Central America T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
10. T CELL THERAPY MARKET-INDUSTRY LANDSCAPE
10.1 Overview
10.2 Growth Strategies in T Cell Therapy Market
10.3 Organic Growth Strategies
10.3.1 Overview
10.4 Inorganic Growth Strategies
10.4.1 Overview
11. COMPANY PROFILES
11.1 Janssen Global Services LLC
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Gilead Sciences Inc
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Bristol-Myers Squibb Co
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Novartis AG
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
12. APPENDIX
12.1 About Us
12.2 Glossary of Terms
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 South & Central America T Cell Therapy Market, by Country (US$ Million)
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. SOUTH & CENTRAL AMERICA T CELL THERAPY MARKET - KEY INDUSTRY DYNAMICS
4.1 Market Drivers:
4.1.1 Growing Burden of Cancer Worldwide
4.1.2 Increasing Number of T-Cell Therapy Approvals
4.2 Market Restraints
4.2.1 Side-effects of CAR T-Cell Therapy
4.3 Market Opportunities
4.3.1 Growing Investment in T-Cell Therapy
4.4 Future Trends
4.4.1 Rising Number of CAR T-Cell Therapies in Clinical Trials
4.5 Impact Analysis:
5. T CELL THERAPY MARKET - SOUTH & CENTRAL AMERICA MARKET ANALYSIS
5.1 South & Central America T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030
6. SOUTH & CENTRAL AMERICA T CELL THERAPY MARKET - REVENUE AND FORECAST TO 2030 - BY MODALITY.
6.1 Overview
6.2 South & Central America T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
6.3 Research
6.3.1 Overview
6.3.2 Research: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Commercialized
6.4.1 Overview
6.4.2 Commercialized: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7. SOUTH & CENTRAL AMERICA T CELL THERAPY MARKET - REVENUE AND FORECAST TO 2030 - BY THERAPY TYPE
7.1 Overview
7.2 South & Central America T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
7.3 CAR T-cell Therapy
7.3.1 Overview
7.3.2 CAR T-cell Therapy: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 T-cell Receptor (TCR)-based.
7.4.1 Overview
7.4.2 T-cell Receptor (TCR)-based: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8. SOUTH & CENTRAL AMERICA T CELL THERAPY MARKET - REVENUE AND FORECAST TO 2030 - BY INDICATION
8.1 Overview
8.2 South & Central America T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
8.3 Hematologic Malignancies
8.3.1 Overview
8.3.2 Hematologic Malignancies: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.3.3 South & Central America T Cell Therapy Market , by Haematological Malignancies, 2020-2030 (US$ Million)
8.4 Solid Tumor
8.4.1 Overview
8.4.2 Solid Tumor: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
9. SOUTH & CENTRAL AMERICA T CELL THERAPY MARKET - COUNTRY ANALYSIS
9.1 Overview
9.1.1 South & Central America T Cell Therapy Market by Country
9.1.1.1 Brazil
9.1.1.1.1 Brazil: South & Central America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.1.2 Brazil: South & Central America T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
9.1.1.1.3 Brazil: South & Central America T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.1.4 Brazil: South & Central America T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.1.4.1 Brazil: South & Central America T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
10. T CELL THERAPY MARKET-INDUSTRY LANDSCAPE
10.1 Overview
10.2 Growth Strategies in T Cell Therapy Market
10.3 Organic Growth Strategies
10.3.1 Overview
10.4 Inorganic Growth Strategies
10.4.1 Overview
11. COMPANY PROFILES
11.1 Janssen Global Services LLC
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Gilead Sciences Inc
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Bristol-Myers Squibb Co
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Novartis AG
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
12. APPENDIX
12.1 About Us
12.2 Glossary of Terms
